[HTML][HTML] Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge
Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
[HTML][HTML] Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge
R Arbel, YW Sagy, M Hoshen, E Battat, G Lavie… - 2022 - researchsquare.com
Background Nirmatrelvir, an inhibitor of the main protease of severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a significant decrease in the risk …
syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a significant decrease in the risk …
[PDF][PDF] Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge
R Arbel, YW Sagy, M Hoshen, E Battat, G Lavie… - paginaum.pt
Background Nirmatrelvir, an inhibitor of the main protease of severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a signi cant decrease in the risk …
syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a signi cant decrease in the risk …
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
R Arbel, YW Sagy, M Hoshen… - The New England …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
R Arbel, YW Sagy, M Hoshen, E Battat… - New England Journal …, 2022 - cir.nii.ac.jp
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
[PDF][PDF] Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge
R Arbel, YW Sagy, M Hoshen, E Battat, G Lavie… - scholar.archive.org
Background Nirmatrelvir, an inhibitor of the main protease of severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a signi cant decrease in the risk …
syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a signi cant decrease in the risk …
Nirmatrelvir use and severe COVID-19 outcomes during the omicron surge.
R Arbel, YW Sagy, M Hoshen, E Battat, G Lavie… - 2022 - cabidigitallibrary.org
BACKGROUND: The oral protease inhibitor nirmatrelvir has shown substantial efficacy in
high-risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
high-risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
[PDF][PDF] Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge
R Arbel, YW Sagy, M Hoshen, E Battat, G Lavie… - academia.edu
Background Nirmatrelvir, an inhibitor of the main protease of severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a signi cant decrease in the risk …
syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a signi cant decrease in the risk …
[HTML][HTML] Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge
R Arbel, YW Sagy, M Hoshen, E Battat, G Lavie… - 2022 - europepmc.org
Background: Nirmatrelvir, an inhibitor of the main protease of severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a significant decrease in the risk …
syndrome coronavirus-2 (SARS-CoV-2), has demonstrated a significant decrease in the risk …
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
R Arbel, YW Sagy, M Hoshen, E Battat… - New England Journal …, 2022 - cris.bgu.ac.il
Background: The oral protease inhibitor nirmatrelvir has shown substantial efficacy in
highrisk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
highrisk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …